University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
HeartSciences (NASDAQ:HSCS) had its price target raised by analysts at Ascendiant Capital Markets from $9.00 to $9.20. They now have a "buy" rating on the stock.
Heart Test Laboratories reports Q2 results [Seeking Alpha]
HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update